Patent US4979150A successfully refreshed from Google Patents.
Patent US4025624A successfully refreshed from Google Patents.
US4025624A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Phenylalkylamines and phenylalkylureas in combinations to suppress gastric bleeding in aspirin therapy
Assignee: AH Robins Co Inc
•
Filing: 1975-11-18
•
Granted: 1977-05-24
•
Expires: 1995-11-18
Abstract
Abstract Novel pharmaceutical methods, combinations and compositions for reducing gastric bleeding during aspirin therapy for inflammation are disclosed. Compounds used in combination with aspirin are phenylalkylamines and phenylalkylureas having the formula: ##STR1## wherein Z is selected from the group consisting of --NHR 2 or ##STR2## and R is selected from the group consisting of hydrogen, halogen, lower-alkoxy and trifluoromethyl and R 1 , R 2 , R 3 and R 4 are selected from the group consisting of hydrogen and lower-alkyl, where R 3 and R 4 taken together with the adjacent nitrogen atom may form a heterocyclic ring selected from the group of piperidino, pyrrolidino, piperazino, and morpholino.
Inventors
- 👤 Reevis Stancil Alphin
- 👤 William John Welstead, Jr.
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-10 01:05
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/60; A61K31/618; A61K31/621
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
72 words
The method of treating inflammatory conditions in mammals which comprises administering to said mammals an effective amount of aspirin and a phenylalkylurea having the formula: ##STR7## wherein; Z is selected from the group consisting of ##STR8## R is selected from the group consisting of hydrogen, chlorine, bromine, fluorine, lower-alkoxy and trifluoromethyl, R 1 , r 2 , r 3 and R 4 are selected from the group consisting of hydrogen and lower-alkyl.
Claim 2
Independent Claim
72 words
The method of treating inflammatory conditions in mammals which comprises administering to said mammals an effective amount of aspirin and a phenylalkylurea having the formula: ##STR7## wherein; Z is selected from the group consisting of ##STR8## R is selected from the group consisting of hydrogen, chlorine, bromine, fluorine, lower-alkoxy and trifluoromethyl, R 1 , r 2 , r 3 and R 4 are selected from the group consisting of hydrogen and lower-alkyl.
Claim 3
Dependent Claim
10 words
The method of claim 1 wherein the compound is 1-methyl-1-(α-methylphenethyl)urea.
Claim 4
Dependent Claim
10 words
The method of claim 1 wherein the compound is 1-(α-methyl-3-trifluoromethylphenethyl)urea.
Claim 5
Dependent Claim
10 words
The method of claim 1 wherein the compound is 1-ethyl-1-(α-methyl-3-trifluoromethylphenethyl)urea.
Claim 6
Dependent Claim
10 words
The method of claim 1 wherein the compound is 1,3-diethyl-1-(α-methyl-3-trifluoromethylphenethyl)urea.
Claim 7
Dependent Claim
10 words
The method of claim 1 wherein the compound is 3-ethyl-1-methyl-1(α-methylphenethyl)urea.
Claim 8
Dependent Claim
87 words
An anti-inflammatory composition for oral administration comprised of (a) a combination of 67 to 99.5 weight % aspirin, and 0.5 to 33.0 weight % of a phenylalkylurea selected from those having the formula ##STR9## wherein; Z is selected from the group consisting of ##STR10## R is selected from the group consisting of hydrogen, chlorine, bromine, fluorine, lower-alkoxy and trifluoromethyl, R 1 , r 2 , r 3 and R 4 are selected from the group consisting of hydrogen and lower-alkyl and (b) A pharmaceutically acceptable carrier therefor.
Claim 9
Dependent Claim
87 words
An anti-inflammatory composition for oral administration comprised of (a) a combination of 67 to 99.5 weight % aspirin, and 0.5 to 33.0 weight % of a phenylalkylurea selected from those having the formula ##STR9## wherein; Z is selected from the group consisting of ##STR10## R is selected from the group consisting of hydrogen, chlorine, bromine, fluorine, lower-alkoxy and trifluoromethyl, R 1 , r 2 , r 3 and R 4 are selected from the group consisting of hydrogen and lower-alkyl and (b) A pharmaceutically acceptable carrier therefor.
Claim 10
Dependent Claim
10 words
A composition of claim 7 wherein the compound is 1-methyl-1-(α-methylphenethyl)urea.
Claim 11
Dependent Claim
10 words
A composition of claim 7 wherein the compound is 1-(α-methyl-3-trifluoromethylphenethyl)urea.
Claim 12
Dependent Claim
10 words
A composition of claim 7 wherein the compound is 1-ethyl-1-(α-methyl-3-trifluoromethylphenethyl)urea.
Claim 13
Dependent Claim
10 words
A composition of claim 7 wherein the compound is 1,3-diethyl-1-(α-methyl-3-trifluoromethylphenethyl)urea.
Claim 14
Dependent Claim
10 words
A composition of claim 7 wherein the compound is 3-ethyl-1-methyl-1(α-methylphenethyl)urea.
Claim 15
Dependent Claim
27 words
A composition of claim 7 in the form of a tablet, aqueous or oily suspension, dispersible powder or granules, emulsion, hard or soft capsule, syrup or elixir.
Claim 16
Dependent Claim
16 words
A composition of claim 7 in the form of a food premix for administration to animals.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-05-23 | 1980-11-22 | 1981-05-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-05-23 | 1984-11-22 | 1985-05-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-05-23 | 1988-11-22 | 1989-05-24 | $7700.00 | Window Closed / Lapsed |